Gene therapy of malignant gliomas: A phase I study of IL-4-HSV-TK gene- modified autologous tumor to elicit an immune response

Human Gene Therapy

Volumn 11, Issue 4, 2000, Pages 637-653

  Okada, Hideho ^a   Pollack, Ian F ^a   Lotze, Michael T ^a   Dade Lunsford, L ^a   Kondziolka, Douglas ^a   Lieberman, Frank ^a   Schiff, David ^a   Attanucci, Jason ^a   Edington, Howard ^a   Chambers, William ^a   Robbins, Paul ^a   Baar, Joe ^a   Kinzler, Donna ^a   Whiteside, Theresa ^a   Elder, Elaine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4;

CLINICAL PROTOCOL; CLINICAL TRIAL; COST; DNA MODIFICATION; ETHICS; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; NOTE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

BRAIN NEOPLASMS; CLINICAL PROTOCOLS; GENE THERAPY; GLIOMA; HUMANS; INTERLEUKIN-4; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSDUCTION, GENETIC;

EID: 0034054582     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015824     Document Type: Note

References (38)

1. Andreansky, S., He, B., Van Cott, J., McGhee, J., Markert, J.M., Gillespie, G.Y., Roizman, B. and Whitley, R.J. (1998) Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5, 121-130.
2. Barks, J.L., McQuillan, J.J. and Iademarco, M.F. (1997) TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J. Immunol. 159, 4532-4538.
3. Benedetti, S., Dimeco, F., Pollo, B., Cirenei, N., Colombo, B.M., Bruzzone, M.G., Cattaneo, E., Vescovi, A., Didonato, S., Colombo, M.P. and Finocchiaro, G. (1997) Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Human Gene Ther. 8, 1345-1353.
4. Blankenstein, T., Li, W., Muller, W. and Diamantstein, T. (1990) Retroviral interleukin 4 gene transfer into an IL-4-dependent cell line results in autocrine growth but not in tumorigenicity. Eur. J. Immunol. 20, 935-938.
5. Bosco, M., Riovarelli, M., Forni, M., Modesti, A., Scarpa, S., Masuelli, L. and Forni, G. (1990) Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145, 3136-3143.
6. Bozik, M.E., Chambers, W.H., Lotze, M.T., Fellows, W., Suhajda, K., Harding, B. and Gilbert, M. (1996) T-cell dependent intracerebral tumor regression of a 9L gliosarcoma expressing mIL-4 in a syngeneic host. Proc. Annu. Meet. Am. Assoc. Cancer. Res. 36, A2800 (Abstract).
7. Cheng, S.Y., Huang, H.J., Nagane, M., Ji, X.D., Wang, D., Shih, C.C., Arap, W., Huang, C.M. and Cavenee, W.K. (1996) Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 93, 8502-8507.
8. Cornetta, K. and Anderson, W.F. (1989) Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene transfer: implications for human gene therapy. J. Viol. Methods 23, 186-194.
9. Cornetta, K. and et al. (1990) Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Human Gene Ther. 1, 13-26.
10. Danos, O. and Mulligan, R.C. (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA 85, 6460-6464.
11. Demicco, C. (1989) Immunology of central nervous system tumors (Review) J. Neuroimmunol. 25, 93-108.
12. Elder, E.M., Lotze, M.T. and Whiteside, T.L. (1996) Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Human Gene Ther. 7, 479-487.
13. Gilbert, M.R., Lunsford, L.D. and Kondziolka, L. (1993) A phase II trial of continuous infusion chemotherapy, external beam radiotherapy and local boost radiotherapy. Proc. Am. Soc. Clin. Oncol. 12, 76 (Abstract).
14. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M. and Pardoll, D.M. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
15. Hitchcock, E.R. and Morris, C.S. (1988) Mononuclear cell infiltration in central portions of human astrocytomas. J. Neurosurg. 68, 432-437.
16. Hu-Li, J., Shevach, E.M., Mizuguchi, J., Ohara, J., Mostmann, T. and Pawl, W.E. (1987) B cell stimulatory factor I (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J. Exp. Med. 165, 157-161.
17. Jacobs, S.K., Wilson, D.J., Kornblith, P.L. and Grimm, E.A. (1986) In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J. Neurosurg. 64, 743-749.
18. Kantoff, P.W. and et al. (1987) Expression of human adenosine deaminase in nonhuman primates after retroviral-mediated gene transfer. J. Exp. Med. 166, 219-234.
19. Kawakami, Y., Rosenberg, S.A. and Lotze, M.T. (1988) Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168, 2183-2191.
20. Li, W., Diamantstein, T. and Blankenstein, T. (1990) Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol. Immunol. 27, 1331-1337.
21. Mahaley, Jr. M.S., Bigner, D.D., Dudka, L.F., Wilds, P.R., Williams, D.H., Bouldin, T.W., Whitaker, J.N. and Bynum, M.S. (1983) Immunobiology of primary intracranial tumors; Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study J. Neurosurg. 59, 201-207.
22. Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Martin Kast, W., Deleo, A.B. and Lotze, M.T. (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity Nature Med. 1, 1297-1302.
23. Miller, D.G., Adam, M.A. and Miller, A.D. (1990) Gene transfer by retrovirus vectors only occurs in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10, 4239-4242.
24. Noelle, R., Kramer, P.H., Ohara, J., Uhr, J.W. and Vitetta, E.S. (1984) Increased expression of Ia antigens on resting B cells. Proc. Natl. Acad. Sci. USA 81, 6149-6153.
25. Okada, H., Attanucci, J., Tahara, H., Pollack, I.F., Bozik, M.E., Chambers, W.H. and Lotze, M.T. (1999a) Characterization and transduction of a retroviral vector encoding human interleukin-4 and the Herpes simplex-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther. in press.
26. Okada, H., Giezeman-Smits, KM., Tahara, H., Attanucci, J., Fellows, WK., Lotze, M.T., Chambers, W.H. and Bozik, M.E. (1999b) Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSV-TK tumor vaccine. Gene Ther. 6, 219-226.
27. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153, 5659-5673.
28. Piali, L., Fichtel, A., Terpe, H.J., Imhof, B.A. and Gisler, R.H. (1995) Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181, 811-816.
29. Pippin, B.A., Rosenstein, M., Jacob, W.F., Chiang, Y., and Lotze, M.T. (1994) Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2. Cancer Gene Ther. 1, 35-42.
30. + progenitor cells. Exp. Hematol. 26, 63-72.
31. Saas, P., Walker, P.R., Hahne, M., Quiquerez, A.L., Schnuriger, V., Perrin, G., French, L., Van Meir, E.G., De Tribolet, N., Tschopp, J. and Dietrich, P.Y. (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J. Clin. Invest. 99, 1173-1178.
32. Sampson, J.H., Ashley, D.M., Archer, G.E., Fuchs, H.E., Dranoff, G., Hale, L.P. and Bigner, D.D. (1997) Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurg. 41, 1365-72.
33. Sawamura, Y., Hosokawa, M., Kuppner, M.C., Kobayashi, H., Aida, T., Abe, H. and De Tribolet, N. (1989) Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res. 49, 1843-1849.
34. Schüler, T., Qin, Z., Ibe, S., Noben-Trauth, N. and Blankenstein, T. (1999) TH1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in IL-4-deficient mice. J. Exp. Med. 189, 803-810.
35. Stoppacciaro, A., Paglia, P., Lombardi, L., Parmiani, G., Baroni, C. and Colombo, M.P. (1997) Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur. J. Immunol. 27, 2375-2382.
36. Tepper, R.I., Pattengale, P.K. and Leder, P. (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57, 503-512.
37. Weller, M. and Fontana, A. (1995) The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res. 21, 128-151.
38. Zitvogel, L., Tahara, H., Cai, Q., Storkus, W.J., Muller, G., Wolf, S.F., Gately, M., Robbins, P.D. and Lotze, M.T. (1994). Construction and characterization of retrovirus vectors expressing biologically active human inteleukin-12. Human Gene Ther. 5, 1493-1506.